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The Authors Reply: We thank Dr Angelotti et al.1 for their
comments regarding our paper deﬁning the ontogeny of CD24
in the human kidney,2 and for their suggestions for the use of
anti-CD133 monoclonal antibodies to the CD133/1 and
CD133/2 epitopes for the selection and puriﬁcation of renal
progenitor cells. We would like to emphasize that the purpose
of our report was to deﬁne, using high quality immunohisto-
chemical analyses of human fetal kidneys, the precise spatial
and temporal localization of CD24, so as to suggest potential
roles of this cell-surface antigen in normal and abnormal
human kidney development.
We of course defer to views of Dr Angelotti et al. regarding
the best technique of isolation of kidney progenitor cells, but
we would disagree with their interpretation of our results on
CD133 expression. In fact, although CD133 expression using
our polyclonal antibody was less restricted than theirs, we did
in fact show co-localization of CD133 and CD24 in early
developing nephron epithelial structures, which, given post-
natal CD133 (or prominin) expression, not surprisingly
express this antigen.
Finally, although the CD133/1 and CD133/2 epitopes may
be more speciﬁc to renal progenitors, we suspect that some of
the differences seen in our work and theirs, may have more to
do with immunohistochemistry technique, sample collection,
and tissue ﬁxation, on the basis of the details of their included
photomicrographs.
1. Angelotti ML, Lazzeri E, Lasagni L et al. Only anti-CD133 antibodies
recognizing the CD133/1 or the CD133/2 epitopes can identify human
renal progenitors. Kidney Int 2010; 78: 620–621.
2. Ivanova L, Hiatt MJ, Yoder MC et al. Ontogeny of CD24 in the human
kidney. Kidney Int 2010; 77: 1123–1131.
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Paraproteinemia-associated
pseudohypercreatininemia across
different analytical methodologies
To the Editor: The case reported by Rudofsky et al.1
illustrated that clinicians and laboratorians need to be
cautious of potential analytical interference secondary to
paraproteinemia. Recently, we encountered an 81-year-old
man with history of IgM k myeloma and elevated creatinine
concentration of 6.5mg/dl (normal: 0.7–1.2mg/dl), deter-
mined using the modiﬁed Jaffe´ method by Roche (Mannheim,
Germany) DP Modular Analytics analyzer. Considering
patient’s poor premorbid status, conservative and supportive
management of renal failure was decided.
The discrepant urea to creatinine ratio and all along normal
potassium concentrations were noticed by the chemical
pathologist. Distorted reaction curve was noted upon data
retrieval. Serial dilution of patient specimen with quality control
material showed the creatinine concentration was only 2.1mg/
dl. Creatinine level was measured as 1.7mg/dl by enzymatic
method with J&J Vitros (Raritan, NJ, USA) dry chemistry ana-
lyzer. Serum cystatin C was 1.17mg/l (normal: 0.50–1.00mg/l).
Physicians were contacted and ﬁndings explained.
Paraproteins interfering with Jaffe´ method for creatinine
determination have been reported.2 Analyses of numerous
clinically important analytes and electrolytes can be interfered
by paraproteins in an extremely unpredictable manner,
affecting different methodologies of automated assays. There
is poor correlation between the subtype and level of
paraproteins and the likelihood of in vitro interference.3
Enhanced clinical alertness helps picking up false results and
prevents patient damages, including anxiety and medication
underdosing. From the laboratory’s perspective, proper
procedures in handling specimens with paraproteins should
be in place and appropriately documented. Platforms with
alternative methodologies should be readily accessible in
processing doubtful cases. Interpretation and authorization of
abnormal results by chemical pathologists can further
minimize reporting misleading results directly from auto-
mated analyzers. Finally, the importance of effective commu-
nications between physicians and chemical pathologists
cannot be overemphasized.
1. Rudofsky G, Villalobos M, Waldherr R et al. The case: renal failure in a male
with Waldenstro¨m’s macroglobulinemia. Kidney Int 2010; 77: 371–372.
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The Authors Reply: Short time after our report of a patient
with pseudohypercreatininemia due to Waldenstro¨m’s macro-
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globulinemia, Kwok et al.1 present a similar case of falsely
elevated creatinine concentration.2 Interestingly, whereas in our
case, Jaffe´ method was superior to enzymatic creatinine
measurement in determining correct renal function, Kwok
et al. report falsely elevated levels using the Jaffe´ method. Assay
interference depends on the subtype of the elevated monoclonal
immunoglobulin M and this may explain the observed
differences.3 Indeed, paraproteinemias, mainly monoclonal
immunoglobulin M, have been reported to inﬂuence different
estimation methods of renal function, putting patients at
potential risks.2–4 Of note, our case and the case by Kwok
et al. measuring cystatin C revealed a correct measurement of
kidney function, suggesting that cystatin C measurement is not
affected by paraproteinemia and is thus a suitable method that
allows the estimation of renal function in these cases.2 If this
proves true, determining cystatin C in patients with monoclonal
gammopathy would prevent potential harm resulting from
medication underdosing and renal replacement therapy. There-
fore, prospective studies are required to determine the value of
cystatin C measurements in patients with paraproteinemias.
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Expression and localization of the
ciliary disease protein retinitis
pigmentosa GTPase regulator in
mammalian kidney
To the Editor: This letter is in reference to the recent article
published by Schafer and colleagues,1 in which they report the
association of retinal disease protein retinitis pigmentosa
GTPase regulator (RPGR) with the modulation of cystic
kidney disease phenotype. We congratulate the authors for
this remarkable ﬁnding.
RPGR mutations predominantly result in retinal degen-
eration. Some patients also exhibit sensorineural hearing loss,
primary cilia dyskinesia, and sperm defects.2,3 In light of the
recent report,1 we would like to provide additional corrobor-
ating evidence linking RPGR to the manifestation of renal
diseases. We showed that RPGR is expressed in mammalian
kidney; an RPGR-immunoreactive band can be detected at
the expected size of B170 kDa in mouse and rat kidney
extracts (Figure 1a). Immunohistochemical analysis further
showed that RPGR localizes to the podocytes in the
glomerulus (Figure 1b) as well as to primary cilia in parietal
epithelium and tubules (Figure 1c and d).
Given a critical role of ciliary function in regulating renal
physiology,4 these studies should heighten the awareness
among clinicians and scientists in this newly recognized
cilia associated renal–retinal connection with RPGR. We
hope that these studies will also lead to further characteriza-
tion of the mechanism of RPGR-associated multisystemic
pathogenesis.
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